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the tangential and supraclavicular fields, allowing for 
implementation of vmDIBH in locoregionally irradiated 
patients. Heart position variation is limited to 2 mm and dose 
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Purpose or Objective: To inform early breast cancer patients 
about postlumpectomy radiotherapy (RT) in group session, 
and to evaluate their knowledge regarding side-effects and 
precautions compared with patients informed by doctors. 
 
Material and Methods: From April 2015 to June 2015, 
patients referred for RT at a single institution were informed 
about RT during one hour group sessions (pilot group). These 
were held twice a month with up to six patients and their 
relatives. The patients and relatives were informed about RT 
preparation procedures, structure of the linac and beams 
effect, side effects, precautions and lifestyle 
recommendations during and after RT, by radiation 
therapists, using power-point presentations. After these 
group sessions, the patients had a 30 min individual 
consultation including an examination by a doctor. The 
patient’s knowledge regarding side-effects and precautions 
were evaluated using a questionnaire that they anonymously 
were asked to answer in connection with the following 
planning CT scan. The same questionnaire was filled in by 
patients before April 2015 (control group), thereby being able 
to compare knowledge of side-effects and precautions during 
RT among patients informed during group sessions compared 
with patients informed by doctors. The two groups were 
compared using chi-square statistics. 
 
Results: 33 patients filled in the questionnaire after 
conventional information and 25 patients after group 
sessions. The following subjects were more often correctly 
answered by patients informed during group sessions: Acute 
toxicity (p< 0.001), sequence of acute events (p=0.16), 
precautions during RT (p=0.006), late toxicity (p=0.07), 
reasons for recommendation of non smoking (p=0.03) and use 
of skin care cream (0.002). The group sessions were 
timesaving for both the radiation therapists and the doctors 
and especially for left sided patients, information about 
respiratory gated RT resulted in reduced scheduled time for 
information. The patients were generally satisfied e.g.one 
said “I wish I was informed that way the last time I was given 
RT “. Participating patients were able to create personal 
relations to other participating patients. The radiation 
therapists were in general content and satisfied by the 
challenge of being responsible for RT information to these 
patients. 
 
Conclusion: Patient’s contentment and level of knowledge 
before initiating RT can be improved by educating and 
preparing the patients for RT during group sessions. These 
group sessions are now implemented as standard information 
procedure for all breast cancer patients, and it is considered 
to expand these sessions to other groups of cancer patients. 
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Purpose or Objective: To investigate the clinical application 
of a technique for patient set-up verification in whole breast 
irradiation after conservative surgery based on a surface 
laser scanning registration system 
 
Material and Methods: Displacements from concurrent 
Sentinel™ (Sentinel®, C-Rad Positioning AB, Sweden) surface 
imaging and Elekata Axesse accelerator cone beam CT (CBCT) 
registrations were compared for 10 patients with breast 
cancer after conservative surgery for a total of 130 set-ups. 
As comparison, the patient outline extracted from the 
planning CT system(Oncentra®, nucletron/Elekta, Sweden) 
was used as Sentinel™ reference (Ctref) and also was used as 
a reference for the CBCT method. Patients were first scanned 
both with surface laser scanning and CBCT, shifted to the 
optimal isocenter position according to CBCT verification. 
And then another optical scan was performed to verify the 
matching in relation to CBCT. Position detection by both 
surface scan and CBCT acquired for the first five fractions of 
radiotherapy and then twice weekly. The data collected by 
both systems were statistical analyzed by paired t-test using 
SPSS 13.0.  
 
 
Results: The absolute translational setup errors (mean ± SD) 
in X (Lateral), Y (Lngitudinal), Z(Vertical) axes detected by 
CBCT prior radiation were 0.21±0.21cm, 0.29±0.26cm and 
0.42±0.22cm respectively; rotational setup errors (mean ± 
SD) in Rx (Pitch), Ry (Roll), Rz (Yaw) axes were 0.83°±0.7, 
1.12°±0.79 and 1.07°±0.81. The absolute translational setup 
errors (mean ± SD) in six directions detected by Sentinel™ 
prior radiation were 0.14±0.18cm, 0.15±0.14, 0.13±0.13, 
0.77°±0.54, 0.76°±0.61 and 1.23°±0.95. The system accuracy 
was better than 1.5 mm and 1.1° when a Sentinel image was 
used as reference. Paired setup errors form Sentinel™ and 
CBCT showed no significant difference in five directions: X 
(t=–1.827, P=0.07), Y (t=0.125, P=0.9), Z (t=1.595, P=0.112) , 
Ry(t=-1.717, P=0.09) and Rz(t=2.382, P=0.6) axes, and 
significant difference in one direction of Rx(t=-3.409, P=0.03) 
axes. 
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Conclusion: The Sentinel™ surface imaging device is a 
reproducible and consistent system able to detect 
misalignments with accuracy. This study shows good 
agreement between the surface scanner and CBCT in patient 
positioning. The Sentinel™ surface imaging system is a good 
supplement to the CBCT system for accurate set-up for 
fractions for whole breast irradiation after conservative 
surgery. 
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Purpose or Objective: Radiotherapy dose escalation using a 
simultaneous integrated boost (SIB) is predicted to improve 
local tumour control in oesophageal cancer patients (Warren 
IJROBP 2014), yet any increase in acute bone marrow toxicity 
could reduce treatment intensity, and limit any predicted 
improvement in patient outcome. In the SCOPE oesophageal 
trial, 28% of patients treated with concurrent 
cisplatin/capecitabine and 50 Gy in 25 fractions experienced 
grade ≥3 haematological toxicity (HT3+) (Crosby Lancet Oncol 
2013). Proton therapy has been shown to significantly reduce 
haematological toxicity in lung cancer patients receiving 
concurrent chemotherapy (Komaki Radiother Oncol 2011); we 
investigate the potential of bone marrow sparing with 
protons compared to photons, in radiotherapy dose 
escalation for oesophageal tumours. 
 
Material and Methods: 21 mid-oesophageal cancer patients 
with their original conformal plan (3D50) (chosen to be a 
representative subset of the SCOPE trial) were used to study 
the bone marrow dose delivered. A surrogate for bone 
marrow was created by outlining the thoracic vertebrae, 
sternum, scapulae, ribs and clavicles using the automatic 
thresholding tool in Eclipse (Varian). Additional plans were 
created retrospectively: a volumetric modulated arctherapy 
plan (VMAT50) with the same dose as 3D50. SIB plans with a 
dose prescription of 62.5 Gy to the high risk sub-region within 
the planning treatment volume were created using VMAT 
(VMAT62.5) and proton therapy plan (IMPT62.5). Bone V20 Gy 
and V10 Gy dose-metrics were recorded and compared across 
all plans using the Wilcoxon test and Holm Bonferroni 
correction for multiple testing. Parameters from 
gynaecological cancers (Bazan IJROBP 2012) were used to 
predict normal tissue complication probability (NTCP) of 
HT3+. 
 
Results: 3D50 plans show the highest NTCP and V20 values 
for each patient. There is no significant difference between 
the VMAT50 and VMAT62.5 plans, although VMAT plans may 
cause a larger bone volume to be irradiated below 10 Gy than 
3D50. IMPT62.5 showed significant sparing for both V10 and 




Conclusion: Proton therapy plans show significant dose 
sparing for bone marrow in the 10-20 Gy dose region thought 
to be correlated with toxicity. These plans are predicted to 
reduce the risk of HT3+ by ~50% compared to photon 
techniques, and could therefore improve treatment efficacy 
of concurrent chemoradiotherapy for oesophageal cancers. 
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Purpose or Objective: The aim of the study was to evaluate 
how the dosimetric benefit of intensity-modulated proton 
therapy (IMPT) translates into estimated toxicity risk 
reduction in patients with locally advanced non-small cell 
lung cancer (NSCLC). In addition, the potential to spare the 
heart with protons and photons was explored.  
 
Material and Methods: Five patients with NSCLC were 
treated with concurrent chemoradiation, using standard lung-
sparing photon volumetric-modulated arc therapy (L-VMAT) 
to 60 Gy in 25 fractions. Three additional treatment plans 
were created for each patient: heart-sparing VMAT (H-VMAT), 
worst-case robust heart-sparing IMPT (H-IMPT), and worst-
case robust lung-sparing IMPT (L-IMPT). Doses to the organs 
at risk (heart, lung) were evaluated. Resulting normal tissue 
complication probability (NTCP) values for radiation 
pneumonitis were estimated using the dose-only QUANTEC 
model and the adjusted QUANTEC model including clinical 
risk factors 1.  
 
Results: With IMPT, both H-IMPT and L-IMPT, DVH parameters 
including the mean lung dose (MLD), the lung volume 
receiving ≥20 Gy (V20L), the mean heart dose (MHD), and the 
volume of the heart receiving ≥30 Gy (V30H) were all 
between 32 – 80% lower compared with L-VMAT (Tab 1). 
Furthermore, at these considerably lower dose levels with 
protons vs photons, the amount of dose redistributed to the 
lungs when the heart was particularly spared was still lower 
with protons (H-IMPT vs L-IMPT: 65% decrease MHD, 11% 
increase MLD), compared with photons (H-VMAT vs L-VMAT: 
62% decrease MHD, 28% increase MLD). Using the dose-only 
QUANTEC model, comparing L-VMAT with L-IMPT, the lung-
dose reductions translated into a reduction in the risk of 
symptomatic radiation pneumonitis between 4.5% to 9.2% 
(average, 5.8%). However, the QUANTEC model adjusted for 
a priori clinical risk factors showed a reduction of 
symptomatic radiation pneumonitis risk in patients without 
clinical risk factors by 2.5% to 5.4% (average, 3.3%) in 
contrast to 14.2% to 26.7% (average, 18.2%) risk reduction in 
patients with the highest a priori risk (Fig 1). For identical 
DVH reductions, and assuming a threshold risk reduction of ≥ 
10% for G2-toxicity required for indicating proton therapy, an 
